Chargement de l’entreprise
Keep exploring
The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B $USA
NBIXNeurocrine Biosciences, Inc.16,9B $USA+
ELANElanco Animal Health Incorporated13,4B $USA
KNSAKiniksa Pharmaceuticals International, plc8,2B $USA+
LQDALiquidia Corporation5,2B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- SUBLOCADE monthly buprenorphine injections74 %
- Sublingual buprenorphine medicines25 %
Les parts du chiffre d'affaires sont des estimations pour six months ended June 30, 2026, pas des chiffres tirés d'un document officiel.
En concurrence avec
- CAMXCamurus
- Braeburn
- ALKSAlkermesC
- Taille
- 7,9B $US
- Marge
- -0,0 %
Ce qu'elle vend4
SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.
Qui l'achète4
- Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
- Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
- Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
- Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
- 2The United States accounted for 85% of net revenue (2025, high).
- 3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
- 4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
- 5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).
Ce qui pourrait mal tourner
- 1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
- 2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
- 3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.
À propos de Indivior Pharmaceuticals, Inc.
Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.
- Siège
- Richmond, Virginia, United States
- Fondée en
- 2014
- Cotée sur
- Nasdaq
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Indivior Pharmaceuticals, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
